



14. O'Brien JT, Thomas A. Vascular dementia. *Lancet* 2015; 386(10004): 1698–706.
15. Pearce LA, McClure LA, Anderson DC, Jacova C, Sharma M, Hart RG, Benavente OR; SPS3 Investigators. Effects of long-term blood pressure lowering and dual antiplatelet treatment on cognitive function in patients with recent lacunar stroke: a secondary analysis from the SPS3 randomised trial. *Lancet Neurol* 2014; 13: 1177–1185.
16. Rusina R, Matěj R, et al. Neurodegenerativní onemocnění. Praha: Mladá fronta 2014: 351.
17. Seppi K, Ray Chaudhuri K, Coelho M, Fox SH, Katzenschlager R, Perez Lloret S, Weintraub D, Sampaio C; and the collaborators of the Parkinson's Disease Update on Non-Motor Symptoms Study Group on behalf of the Movement Disorders Society Evidence-Based Medicine Committee. Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review. *Mov Disord* 2019; 34(2): 180–198.
18. Shivanand P. Review on Alzheimer's disease: its cause, symptoms, and treatment at worldwide. *International Journal of Applied Biology and Pharmaceutical Technology* 2009; 1(1): 112–120.
19. Šonka K. Porucha chování v REM spánku. *Neurol. praxi*, 2008; 9(5): 297–299.
20. Taylor DM, Barnes TRE, Young AH. *The Maudsley prescribing guidelines in psychiatry*. 13th ed. West Sussex, United Kingdom: John Wiley & Sons 2018; 854.
21. Tsai RM, Boxer AL. Therapy and clinical trials in frontotemporal dementia: past, present, and future. *J Neurochem*. 2016; 138(Suppl 1): 211–221.
22. Youdim MB, Oh YJ. Promise of neurorestoration and mitochondrial biogenesis in Parkinson's disease with multi target drugs: an alternative to stem cell therapy. *Exp Neurobiol* 2013; 22: 167–72.
23. Walker Z, Possin KL, Boeve BF, Aarsland D. Lewy body dementias. *Lancet* 2015; 386(10004): 1683–1697.
24. WHO 2017. <http://www.who.int/features/factfiles/dementia/en/>.